Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems

The delivery of recombinant proteins, peptides, antisense agents, and non-viral gene medicines to brain via a trans-vascular route following intravenous administration is possible with the development of blood-brain barrier drug targeting technology. Drugs or genes are re-formulated and attached to molecular Trojan horses that ferry the drug or gene into brain via receptor-mediated transport across the BBB on endogenous peptide transport systems.